SkyQuest Technology Group recently introduced Type 2 Diabetes Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The major factor driving the type 2 diabetes market growth forward is the rising incidence of T2D across the globe. As the incidence of T2D worldwide continues to grow, the global needs for effective treatment options continue to increase accordingly.
Type 2 Diabetes Market size was valued at USD 36.87 Billion in 2023 and is poised to grow from USD 39.72 Billion in 2024 to USD 71.66 Billion by 2032, growing at a CAGR of 7.72% during the forecast period (2025-2032).
The Type 2 Diabetes Market is witnessing notable growth due to increasing demand across various industries and advancements in technology. Factors such as rising consumer awareness, evolving regulations, and the push for sustainable and innovative solutions are driving market expansion. Additionally, the adoption of Type 2 Diabetes Market is fueled by its versatile applications and growing focus on efficiency, quality, and performance.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/type-2-diabetes-market
Moreover, pharmaceutical companies are supporting the growth of the market by developing new drugs. Importantly, new drugs such as sodium-glucose cotransporter-2 (SGLT2) inhibitors such as Jardiance and glucagon-like peptide-1 receptor agonists Tanzeum and Trulicity have provided significant advances in the management of diabetes. These have increasingly been gaining popularity for they provide better alternatives for treatment to patients with fewer side effects.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Type 2 Diabetes Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Global Type 2 Diabetes Market is segmented by Drug Class, Route of Administration, Distribution Channel, End User, and Region.
Based on Drug Class, the market is segmented into Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Biguanides, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors, Others.
Based on Route of Administration, the market is segmented into Oral, Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Based on End User, the market is segmented into Homecare Settings, Hospitals & Clinics, Academic & Research Institutes, Others.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Type 2 Diabetes Market – Regional Analysis:
In 2022, North America was the market leader for type 2 diabetes, accounting for 35% of the revenue share. The expansion of this market is driven by the rapid rise in the prevalence of diabetes in this region. More than 29 million people in North America are thought to have diabetes at the moment, and by 2025, that figure is predicted to increase to 32 million, which will increase demand for diabetes care goods and services.
Diabetes is one of the key market drivers, as more than 25 million people suffer from the disease in the US alone in 2019. North America is dominant due to its high prevalence, increasing awareness, availability of advanced therapies, and a strong healthcare system. Availability of newer pharmaceutical treatments and the increasing use of digital health solutions also add to the region’s market growth.
Top Market Players in Type 2 Diabetes Market are:
Novo Nordisk
Sanofi
Eli Lilly and Company
Merck & Co., Inc.
Boehringer Ingelheim
AstraZeneca PLC
Novartis AG
GlaxoSmithKline plc
Pfizer Inc.
Daiichi Sankyo Company, Limited
Roche Holding AG
Sun Pharmaceutical Industries Ltd.
Lupin Limited
Dr. Reddy’s Laboratories Ltd.
Aurobindo Pharma Limited
Medtronic
B. Braun Melsungen AG
Abbott Laboratories
F. Hoffmann-La Roche
Insulet Corporation
For a customized report, contact us to request personalization – https://www.skyquestt.com/speak-with-analyst/type-2-diabetes-market
Recent Developments:
Novo Nordisk’s Ozempic launch, semaglutide launched in July 2023, is a great improvement in the management of risk of cardiovascular events in Type 2 diabetes patients. With its once-weekly injectable GLP-1 receptor agonist, this may well be an added success in Novo Nordisk’s efforts to enhance patients’ outcomes and deal with diabetes-related cardiovascular problems.
Sanofi’s FDA approval of Toujeo® Max SoloStar® in November 2022 is a significant development in the Type 2 diabetes industry. The launch of Toujeo® Max SoloStar®, an insulin glargine injection with three times the maximum dosage of Toujeo® SoloStar®, significantly expands Sanofi’s diabetes drug portfolio. Patients with Type 2 diabetes enjoy better glucose control and greater dosage flexibility with this injection.
Eli Lilly’s acquisition of Protomer Technologies in March 2021 is a strategic move toward innovative diabetic solutions. Protomer Technologies is specialized in peptide engineering. Its distinct molecular engineering platform may lead to better diabetes treatments, such as insulin that reacts to glucose. This acquisition shows Eli Lilly’s dedication to creating innovative new strategies for treating Type 2 diabetes, which is promising for future therapeutic developments.
Take Action Now: Secure Your Type 2 Diabetes Market Today – https://www.skyquestt.com/buy-now/type-2-diabetes-market
Forward-Looking Insights
The Type 2 Diabetes Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
